Nanoform Finland PLC (fra:4YL) Share Price

Company Profile

Business description
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
Contact
Cultivator II, Viikinkaari 4
Helsinki00790
FIN
T: +358 293700150
https://www.nanoform.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
108

Recommended

There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.

Malik Ahmed Khan, CFA | 11 November 2026

Strong fundamentals meet a demanding valuation.

Esther Holloway | 11 November 2026

As some commodity prices cool, mining valuations look less demanding.

Tyger Fitzpatrick | 11 November 2026

Index	Last price	Change	% Change
All Ordinaries	9,291.30	23.50	0.25%
CAC 40	8,332.87	54.28	0.66%
DAX 40	26,662.77	315.32	1.20%
Dow JONES (US)	52,485.56	253.67	0.49%
FTSE 100	10,835.47	83.88	0.78%
HKSE	24,315.92	241.12	-0.98%
NASDAQ	25,536.77	470.90	1.88%
Nikkei 225	61,248.59	789.01	1.31%
NZX 50 Index	14,179.86	12.45	0.09%
S&P 500	7,628.63	107.70	1.43%
S&P/ASX 200	9,153.20	24.20	0.27%
SSE Composite Index	3,680.64	16.92	0.46%